Cost-effectiveness and return on investment of 20-valent pneumococcal conjugate vaccine use among adults in England: analysis from the societal perspective.
Saved in:
| Title: | Cost-effectiveness and return on investment of 20-valent pneumococcal conjugate vaccine use among adults in England: analysis from the societal perspective. |
|---|---|
| Authors: | Mendes D; Pfizer Ltd., Tadworth, UK. Diana.Mendes@pfizer.com., Averin A; Avalere Health, Washington, DC, USA., Atwood M; Avalere Health, Washington, DC, USA., Sato R; Pfizer Inc., Collegeville, PA, USA., Vyse A; Pfizer Ltd., Tadworth, UK., Campling J; Pfizer Ltd., Tadworth, UK., Hariharan D; Avalere Health, Washington, DC, USA., Weycker D; Avalere Health, Washington, DC, USA., Mugwagwa T; Pfizer Ltd., Tadworth, UK., Vietri J; Pfizer Inc., Collegeville, PA, USA. |
| Source: | Cost effectiveness and resource allocation : C/E [Cost Eff Resour Alloc] 2026 Jan 21; Vol. 24 (1), pp. 31. Date of Electronic Publication: 2026 Jan 21. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101170476 Publication Model: Electronic Cited Medium: Print ISSN: 1478-7547 (Print) Linking ISSN: 14787547 NLM ISO Abbreviation: Cost Eff Resour Alloc Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1478-7547 |
|---|---|
| DOI: | 10.1186/s12962-025-00709-6 |
